Trastuzumab has led to meaningful improvements in survival in early-stage and metastatic ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer.1,2 Trastuzumab is generally well tolerated but is associated with infrequent cardiac dysfunction, manifested most often as an asymptomatic decline in left ventricular ejection fraction (LVEF).1-6
Brann AM, Cobleigh MA, Okwuosa TM. Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016;2(9):1123–1124. doi:10.1001/jamaoncol.2016.1288
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.